HGH Fragment 176-191
HGH Fragment 176-191 is a peptide fragment derived from human growth hormone studied in preclinical research for its potential effects on fat metabolism and tumor targeting. It is a research chemical and is not FDA-approved for human use or clinical applications.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide consisting of amino acids 176 to 191 of the human growth hormone (hGH) molecule. This fragment has been isolated and studied to investigate its distinct biological activities separate from the full-length hormone. It was initially developed to explore mechanisms related to fat metabolism and to potentially harness selective effects of hGH without broader systemic actions.
Originating from studies on human growth hormone's structure-function relationships, HGH Fragment 176-191 has attracted research interest due to its unique ability to influence lipid metabolism pathways. Unlike the full hormone, this fragment is thought to act locally or selectively on metabolic tissues.
In the context of research, this peptide is used primarily to investigate effects on fat reduction, energy metabolism, and more recently, its interactions with tumor-related proteins. Researchers study it to better understand its potential role in enhancing drug delivery or efficacy, particularly in oncology models, as well as its metabolic effects in vitro and in animal models.
HGH Fragment 176-191 is identified chemically by its molecular formula C80H127N23O24S2 and molecular weight of 1859.1 g/mol. It is available exclusively for laboratory research purposes and is not approved for therapeutic use.
Key Benefits & Mechanisms
- Potential Fat Metabolism ModulationPreclinical research has explored HGH Fragment 176-191 for its effects on lipid metabolism, suggesting it may influence fat breakdown and reduce adipose tissue mass in experimental models. These investigations focus on understanding how this fragment can selectively stimulate pathways involved in lipolysis without the broad endocrine effects of full-length human growth hormone.
- Enhancement of Chemotherapeutic Drug EfficacyRecent studies indicate that HGH Fragment 176-191 can interact with tumor-related proteins, potentially increasing the binding affinity of chemotherapeutic agents such as doxorubicin to cancer cell receptors. This mechanism may lead to improved drug accumulation and localized cytotoxic effects within tumors, enhancing the anticancer efficacy of drug delivery systems in preclinical breast cancer models.
- Targeted Tumor InteractionThe peptide’s ability to bind specifically to proteins expressed in tumor cells has been investigated for its role in targeting and modulating receptor interactions. This property is being studied as a strategy to improve the selectivity and potency of anticancer therapies, particularly when combined with nanoparticle-based drug carriers.
- Research Tool for Growth Hormone Fragment BiologyBeyond therapeutic potential, HGH Fragment 176-191 serves as a valuable research tool to dissect the biological activities of the C-terminal region of human growth hormone. It aids in elucidating the molecular mechanisms underlying hormone fragment-specific effects distinct from the intact protein, contributing to broader endocrinological and metabolic research.
Mechanism of action
HGH Fragment 176-191 exerts its effects primarily through interactions with tumor-related proteins, which modulate receptor binding dynamics on cancer cells. This peptide enhances the binding affinity of chemotherapeutic agents like doxorubicin to breast cancer cell receptors, thereby increasing drug accumulation within tumor tissue. The mechanism involves peptide-mediated alteration of receptor conformation or availability, facilitating improved local cytotoxicity and potentially augmenting the therapeutic efficacy of anticancer drugs in preclinical models. Additionally, its selective action on lipid metabolism pathways is hypothesized to influence fat breakdown independent of the full growth hormone receptor signaling cascade.
Research Summary
Research into HGH Fragment 176-191 has focused on its role in enhancing chemotherapeutic drug efficacy and its metabolic effects. A key study titled "Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells" (2022) explored this peptide’s potential to improve cancer treatment outcomes.
This study combined in silico molecular docking simulations with in vitro viability assays to evaluate how HGH Fragment 176-191 affects doxorubicin binding and cytotoxicity in breast cancer cells. The simulations indicated that the peptide increases the binding affinity of doxorubicin to breast cancer receptors by interacting with tumor-specific proteins. Experimental results in MCF-7 cells confirmed enhanced anticancer efficacy when the peptide was included with doxorubicin-loaded chitosan nanoparticles compared to doxorubicin alone.
These findings suggest that HGH Fragment 176-191 may serve as a targeting ligand to augment drug delivery and localize cytotoxic effects within tumors. Although initial preclinical results are promising, further research is required to fully elucidate its mechanisms and potential applications in cancer therapeutics and metabolic regulation.
Dosing in Research Literature
Currently, dosing protocols for HGH Fragment 176-191 in research are not well-established and vary depending on the experimental model and objectives. In vitro studies often utilize micromolar concentrations to evaluate cellular effects, while in vivo animal studies may employ doses calibrated to body weight, but precise standardized dosing ranges have not been definitively characterized in the literature.
Because this peptide is primarily used in preclinical research, dosing regimens are typically designed to investigate mechanistic outcomes rather than therapeutic endpoints. Researchers generally select concentrations based on prior dose-response assessments within their specific experimental systems. No clinical dosing guidelines exist due to the lack of regulatory approval and human trials.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about HGH Fragment 176-191
Is HGH Fragment 176-191 approved by the FDA for human use?
No, HGH Fragment 176-191 is not approved by the U.S. Food and Drug Administration (FDA) for any therapeutic or clinical use. It remains a research chemical intended exclusively for laboratory studies and preclinical investigation.
What is HGH Fragment 176-191 studied for in research?
This peptide fragment is primarily studied for its potential to modulate fat metabolism and enhance the efficacy of chemotherapeutic drugs by targeting tumor-related proteins. Research focuses include its effects on lipid breakdown and its ability to increase drug accumulation in cancer cells.
How does HGH Fragment 176-191 work mechanistically?
HGH Fragment 176-191 interacts with tumor-associated proteins to modify receptor binding affinities, thereby enhancing the uptake and cytotoxicity of anticancer drugs like doxorubicin. It also influences metabolic pathways related to fat metabolism through mechanisms distinct from full-length growth hormone signaling.
Can HGH Fragment 176-191 be combined with other peptides?
In research contexts, HGH Fragment 176-191 has been studied in combination with peptides such as AOD-9604, GHRP-6, and GHK-Cu to explore potential synergistic effects on metabolism, tissue repair, and growth hormone-related pathways. These combinations are experimental and remain within preclinical investigation.
How should HGH Fragment 176-191 be stored and handled in the laboratory?
As a synthetic peptide, HGH Fragment 176-191 should be stored according to manufacturer recommendations, typically under refrigerated or frozen conditions to maintain stability. It should be handled using standard laboratory precautions to avoid contamination and degradation, ensuring integrity for research use.
Legal & research status: Research use only — not approved by the FDA for human use. Sold and discussed for laboratory and research use only, not for human consumption.